We've eagerly awaited the data; now published @NEJM nejm.org/doi/pdf/10.105…
Significant benefit for 27% ⬇️time to recovery, across all subgroups except those on a ventilator/ECMO, death reduced 30% (95% CI 0.47, 1.04; NS)
Overall remdesivir is a safe and effective drug for #COVID19 patients with lower respiratory tract involvement.
For all patients enrolled, the 30%⬇️ deaths is consistent in direction and magnitude as the ⬆️ 27% recovery time.
Patients w/ most severe baseline status derived no benefit.